Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCellular and Molecular

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Flavio Solca, Goeran Dahl, Andreas Zoephel, Gerd Bader, Michael Sanderson, Christian Klein, Oliver Kraemer, Frank Himmelsbach, Eric Haaksma and Guenther R. Adolf
Journal of Pharmacology and Experimental Therapeutics November 2012, 343 (2) 342-350; DOI: https://doi.org/10.1124/jpet.112.197756
Flavio Solca
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Goeran Dahl
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Zoephel
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerd Bader
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Sanderson
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Klein
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Kraemer
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Himmelsbach
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Haaksma
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guenther R. Adolf
Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 343 no. 2 342-350
DOI 
https://doi.org/10.1124/jpet.112.197756
PubMed 
22888144

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received June 25, 2012
  • Accepted August 9, 2012
  • Published online October 15, 2012.

Article Versions

  • Earlier version (August 10, 2012 - 08:51).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Flavio Solca,
  2. Goeran Dahl1,
  3. Andreas Zoephel,
  4. Gerd Bader,
  5. Michael Sanderson,
  6. Christian Klein,
  7. Oliver Kraemer,
  8. Frank Himmelsbach,
  9. Eric Haaksma, and
  10. Guenther R. Adolf
  1. Boehringer Ingelheim RCV GmbH & Co. KG., Vienna, Austria (F.S., G.D., A.Z., G.B., M.S., C.K., O.K., E.H., G.R.A.); and Boehringer Ingelheim Pharma GmbH & Co. KG., Biberach/Riss, Germany (F.H.)
  1. Address correspondence to:
    Flavio Solca, Doktor-Böhringer-Gasse 5-11, A-1120, Vienna, Austria, E-mail: flavio.solca{at}boehringer-ingelheim.com
  • ↵1Current affiliation: AstraZeneca R&D, Mölndal, Sweden.

View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2012 to December 2023

AbstractFullPdf
Aug 20122570193
Sep 20121184237
Oct 201255361241
Nov 201242865134
Dec 20121453696
Jan 20131643793
Feb 20131503183
Mar 201315231108
Apr 20131333963
May 2013962864
Jun 2013763885
Jul 2013944496
Aug 20131314272
Sep 20131524495
Oct 20132354593
Nov 20139097168
Dec 20137510398
Jan 201455100121
Feb 201471100123
Mar 201493121118
Apr 201410590183
May 201486140197
Jun 201457142113
Jul 201486127102
Aug 20145512292
Sep 201470120111
Oct 201479103121
Nov 201410311997
Dec 2014828565
Jan 2015759080
Feb 2015637083
Mar 20158613993
Apr 201571152102
May 201579142107
Jun 20158018287
Jul 201553104101
Aug 20154910382
Sep 20156114491
Oct 20156211982
Nov 201576131122
Dec 20157712586
Jan 2016101112104
Feb 20167811787
Mar 201683143117
Apr 20168512496
May 201670125107
Jun 201671115142
Jul 201672123131
Aug 201687123100
Sep 20165613471
Oct 20164518995
Nov 20163613992
Dec 20161313381
Jan 20172715574
Feb 20172115089
Mar 20172319792
Apr 20173312577
May 20173510686
Jun 20172314277
Jul 20172814288
Aug 20172320177
Sep 20172111965
Oct 20173011185
Nov 20173213554
Dec 20172512163
Jan 20182912481
Feb 20183311361
Mar 20183915095
Apr 20182912588
May 20182514069
Jun 20181511948
Jul 2018248569
Aug 20182010155
Sep 2018149154
Oct 20182115680
Nov 20181613361
Dec 20181564436
Jan 20191502816
Feb 20191363130
Mar 20192053338
Apr 20192372017
May 20191331417
Jun 20192112525
Jul 20191773026
Aug 20191341931
Sep 20191153422
Oct 20191553530
Nov 20191953923
Dec 20192091418
Jan 20201441715
Feb 20201611312
Mar 20201482228
Apr 20202884332
May 20202483030
Jun 2020121914
Jul 2020160917
Aug 20201111418
Sep 2020145711
Oct 20201481818
Nov 20201661617
Dec 20201691119
Jan 20211922124
Feb 20211292824
Mar 20212383532
Apr 20212262214
May 20212752137
Jun 20211671620
Jul 20211992221
Aug 20211503423
Sep 20211451922
Oct 20211742025
Nov 20212201735
Dec 20211822323
Jan 20221312228
Feb 20221651321
Mar 20221912919
Apr 20222092528
May 20221661916
Jun 20221302118
Jul 202210165
Aug 20221011727
Sep 20221683018
Oct 20221041716
Nov 20221732817
Dec 20221181018
Jan 20231971310
Feb 20231972119
Mar 20232162214
Apr 20231191118
May 20231472415
Jun 20231201414
Jul 20231131710
Aug 202310778
Sep 2023201179
Oct 20233882125
Nov 20235141911
Dec 20231141

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 343 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 343, Issue 2
1 Nov 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCellular and Molecular

Afatinib, an Irreversible Inhibitor of EGFR, HER2, and ErbB4

Flavio Solca, Goeran Dahl, Andreas Zoephel, Gerd Bader, Michael Sanderson, Christian Klein, Oliver Kraemer, Frank Himmelsbach, Eric Haaksma and Guenther R. Adolf
Journal of Pharmacology and Experimental Therapeutics November 1, 2012, 343 (2) 342-350; DOI: https://doi.org/10.1124/jpet.112.197756

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCellular and Molecular

Afatinib, an Irreversible Inhibitor of EGFR, HER2, and ErbB4

Flavio Solca, Goeran Dahl, Andreas Zoephel, Gerd Bader, Michael Sanderson, Christian Klein, Oliver Kraemer, Frank Himmelsbach, Eric Haaksma and Guenther R. Adolf
Journal of Pharmacology and Experimental Therapeutics November 1, 2012, 343 (2) 342-350; DOI: https://doi.org/10.1124/jpet.112.197756
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Nitrogen Mustard-Induced Ocular Toxicity
  • Effect of CBG and EAA on UVA-Irradiated Keratinocytes
  • Detecting Cancer-Immune Intercellular Interactions
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics